Multiethnic Cancer Study to Sequence 75,000 Samples for New Genetic Insights

Multiethnic Cancer Study to Sequence 75,000 Samples for New Genetic Insights

The Multiethnic Cohort (MEC) Study, which has monitored the health of adults from Southern California and Hawaiʻi for more than 25 years, will now add a new type of detailed genetic data known as whole exome sequencing. The analysis of nearly 75,000 de-identified participant samples will be funded and conducted by Regeneron Genetics Center® (RGC®), a research initiative that applies genomics and other omics to understanding the underlying causes of human health and disease, and is a subsidiary of Regeneron Pharmaceuticals. The new data can help researchers better predict who will develop cancer and why, supporting more targeted screening and prevention efforts.

The MEC, a collaboration between the Center for Genetic Epidemiology at the Keck School of Medicine of USC and the University of Hawaiʻi that began recruiting participants in 1993, is one of the nation’s most diverse long-term studies of cancer and other diseases. It includes detailed data on diet, lifestyle and medical history from more than 215,000 men and women. Of those, researchers collected blood samples and genetic data from 11,000 African Americans, 24,200 Japanese Americans, 17,200 Latinos, 5,500 Native Hawaiians, 14,600 whites and 500 people of other races or ethnicities. By linking these data with information from state registries on who develops cancer, researchers have gained important insights about cancer risk, including how it varies across populations.

So far, MEC researchers have primarily studied common genetic variation through genome-wide association studies (GWAS), which scan the genome for common variants linked to cancer. Whole exome sequencing complements this approach by reading the protein-coding regions of DNA, allowing researchers to identify rare genetic variants that GWAS may miss.

“Adding whole exome sequencing data is very important to our understanding of who gets cancer and why. It allows us to zoom in on rare genetic variation and can ultimately improve our predictive models of who is at risk,” said Christopher Haiman, ScD, professor of population and public health sciences, director of the Center for Genetic Epidemiology and the AFLAC Chair in Cancer Research at the Keck School of Medicine, and co-principal investigator of the MEC.

The power of whole exome sequencing

Sequencing of de-identified MEC samples is expected to be completed in 2027, at which point Haiman and his colleagues will begin analyzing the results. The data may help them identify uncommon forms of genetic risk for cancer, including variants that are extremely rare or previously unknown.

Researchers will also be able to conduct new types of analyses, including studying copy number variation—extra or missing stretches of DNA that can alter how genes function—and exploring whether known variants associated with one type of cancer also play a role in others.

“At RGC, we are proud to establish strategic collaborations that bring together information from a wide range of populations and healthcare settings, generating richer insights into human biology at unprecedented scale. Our work with USC and the University of Hawaiʻi will hopefully enable deeper insight into human health and guide advances in the prevention and treatment of cancer,” said Goncalo Abecasis, PhD, Senior Vice President, Chief Genomics and Data Sciences Officer, RGC.

The expanded dataset will position USC researchers to launch or join larger consortium studies, where MEC data is combined with other cohorts and biobanks, Haiman said. These collaborations bring together enough participants to study rare genetic variants, which may occur in too few people in a single study to determine whether they are linked to cancer risk.

“The diversity of the MEC is especially important for studying rare variants, because a variant that is very rare overall may be more common in certain populations,” Haiman said.

Building better risk models

The MEC’s diversity also helps researchers refine cancer risk predictions to better account for genetic differences across populations.

“The real significance of this work is to increase the diversity of the data going into these predictive models, which has historically been lacking,” Haiman said. “We’re no longer just developing risk predictions for one population and assuming they will work equally well for others.”

The addition of whole exome sequencing data—and potentially future “omics” data on proteins and other molecules in the body—could make these predictive models even more comprehensive, Haiman said.

In addition to their work on cancer risk, Keck School of Medicine researchers have used MEC data to study DNA changes related to smoking and to reveal chronic health risks among Native Hawaiians. MEC data is also increasingly being used in the USC Center for Genetic Epidemiology to study environmental factors such as air pollution and per- and polyfluoroalkyl substances (PFAS), as potential risk factors for cancer and other chronic diseases.

About this research

The Multiethnic Cohort study is a collaboration between USC and the University of Hawaiʻi, with long-standing support from the National Cancer Institute and the USC Norris Comprehensive Cancer Center. Whole exome sequencing of the MEC is supported by Regeneron Genetics Center.

No Comments Yet

Leave a Reply

Your email address will not be published.